Back to Authors

Dickey, Chad A.

https://orcid.org/0000-0003-3834-3159

Mayo Clinic

USF Health Byrd Alzheimer's Institute

Citations 11

O4‐04‐08: Neuronal tau‐specific stress induction of molecular chaperones: The failure of a coping mechanism
O’Leary, John C., Brady, Sarah, Jinwal, Umesh K., Lewis, Jada , Dickey, Chad A. , Abisambra, Jose F. , Cannon, Ashley , Espinosa, Adriana , Koren, John , Blair, Laura J.

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_20 | Pages: No page available

10.1016/j.jalz.2011.05.1996 Get It

The Diarylheptanoid (+)-aR,11S-Myricanol and Two Flavones from Bayberry (Myrica cerifera) Destabilize the Microtubule-Associated Protein Tau
Jones, Jeffrey R. , Lebar, Matthew D. , Jinwal, Umesh K., Abisambra, Jose F. , Koren, John , Blair, Laura J. , O’Leary, John C., Davey, Zachary , Trotter, Justin H. , Johnson, Amelia G., Weeber, Edwin J. , Eckman, Christopher B., Baker, Bill J. , Dickey, Chad A.

Journal of Natural Products | December 8, 2010 | Volume: 74 | Issue: 1 | Pages: 38-44

10.1021/np100572z Get It

P3‐425: Chaperone‐mediated modulation of tau aggregation correlates with modifications in tau pathology and synaptic plasticity
Kraft, Clara, Rogers, Justin, Jinwal, Umesh K., Johnson, Amelia G., Jansen‐West, Karen , Banko, Jessica L., Golde, Todd E. , Weeber, Edwin J. , Dickey, Chad A. , Abisambra, Jose F. , Blair, Laura J. , Jones, Jeffrey R. , Hill, Shannon E. , Koren, John , Lawson, Lisa Y. , Muschol, Martin

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_19 | Pages: No page available

10.1016/j.jalz.2010.05.1968 Get It

O1‐06–03: Akt functions to regulate the chaperone complex and attenuate Tau degradation
Dickey, Chad A. , Xu, Yafei , Jinwal, Umesh K., Bailey, Rachel M. , Dunmore, Judith, Morgan, Dave, Petrucelli, Leonard , Koren, John , Zhang, Yong‐Jie , Birnbaum, Morris J.

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2008.05.258 Get It

Akt and CHIP coregulate tau degradation through coordinated interactions
Dickey, Chad A. , Koren, John , Zhang, Yong‐Jie , Xu, Ya-Fei, Jinwal, Umesh K., Birnbaum, Morris J. , Monks, Bobby R., Sun, Mei , Cheng, Jin , Patterson, Cam, Bailey, Rachel M. , Dunmore, Judith, Soresh, Sareh, Leon, Carlos M.M.P., Morgan, Dave, Petrucelli, Leonard , Zhang, Yong-Jie

Proceedings of the National Academy of Sciences | February 21, 2008 | Volume: 105 | Issue: 9 | Pages: 3622-3627

10.1073/pnas.0709180105 Get It

A hallmark of the pathology of Alzheimer's disease is the accumulation of the microtubule-associated protein tau into fibrillar aggregates. Recent studies suggest that they accumulate because cytosolic chaperones fail to clear abnormally phosphorylated tau, preserving a pool of toxic tau intermediates within the neuron. We describe a mechanism for tau clearance involving a major cellular kinase, Akt. During stress, Akt is ubiquitinated and degraded by the tau ubiquitin ligase CHIP, and this largely depends on the Hsp90 complex. Akt also prevents CHIP-induced tau ubiquitination and its subsequent degradation, either by regulating the Hsp90/CHIP complex directly or by competing as a client protein with tau for binding. Akt levels tightly regulate the expression of CHIP, such that, as Akt levels are suppressed, CHIP levels also decrease, suggesting a potential stress response feedback mechanism between ligase and kinase activity. We also show that Akt and the microtubule affinity-regulating kinase 2 (PAR1/MARK2), a known tau kinase, interact directly. Akt enhances the activity of PAR1 to promote tau hyperphosphorylation at S262/S356, a tau species that is not recognized by the CHIP/Hsp90 complex. Moreover, Akt1 knockout mice have reduced levels of tau phosphorylated at PAR1/MARK2 consensus sites. Hence, Akt serves as a major regulator of tau biology by manipulating both tau kinases and protein quality control, providing a link to several common pathways that have demonstrated dysfunction in Alzheimer's disease.
Commentary on “Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.” The last stand: The dichotomy of chaperone function in Alzheimer's disease
Dickey, Chad A. , Petrucelli, Leonard

Alzheimer's & Dementia | November 3, 2006 | Volume: 3 | Issue: 1 | Pages: 3-6

10.1016/j.jalz.2006.09.001 Get It

P3–319: Manipulating components of the heat shock response as a therapeutic strategy for tauopathies
Dickey, Chad A. , Petrucelli, Leonard , Hutton, Michael , Eckman, Christopher B., Kamal, Adeela

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_15 | Pages: No page available

10.1016/j.jalz.2006.05.1589 Get It

P3–294: The impact of chip on neurodegenerative diseases
Petrucelli, Leonard , Dickey, Chad A. , Hutton, Mike, Patterson, Cam, Dickson, Dennis W. , Caldwell, Guy A.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_15 | Pages: No page available

10.1016/j.jalz.2006.05.1563 Get It

HSP induction mediates selective clearance of tau phosphorylated at proline‐directed Ser/Thr sites but not KXGS (MARK) sites
Dickey, Chad A. , Dunmore, Judith, Lu, Bingwei , Wang, Jiwu , Lee, Chris W. , Kamal, Adeela , Burrows, Francis , Eckman, Christopher B., Hutton, Michael , Petrucelli, Leonard , Lu, Bingwei

The FASEB Journal | February 7, 2006 | Volume: 20 | Issue: 6 | Pages: 753-755

10.1096/fj.05-5343fje Get It

ABSTRACT Neurofibrillary tangles (NFTs) are a characteristic neuropathological feature of Alzheimer's disease (AD), and molecular chaperones appear to be involved in the removal of disease‐associated hyperphosphorylated tau, a primary component of NFTs. Here, novel HSP90 inhibitors were used to examine the impact of chaperone elevation on clearance of different tau species in transfected cells using a unique quantitative assay. The HSP90 inhibitors reduced levels of tau phosphorylated at proline‐directed Ser/Thr sites (pS202/T205, pS396/S404) and conformationally altered (MC‐1) tau species, an epitope that is immeasurable by standard Western blot techniques. The selective clearance of these phospho‐tau species and MC‐1 tau was mediated via the proteasome, while lysosomal‐mediated tau degradation seems to lack specificity for certain tau species, suggesting a more general role in total tau removal. Interestingly, tau phosphorylated at S262/S356 within the tau microtubule binding domain was minimally affected by chaperone induction. Overall, our data show that chaperone induction results in the selective clearance of specific phospho‐tau and conformationally altered tau species mediated by the proteasome; however, the apparent stability of pS262/S356 tau may also explain why MARK is able to regulate normal tau function yet still be linked to the initiation of pathogenic tau hyperphosphorylation in AD.
Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy
Lee, Chris W. , Courtenay, Andrew, Troendle, Frederick J., Stallings‐Mann, Melody , Dickey, Chad A. , DeLucia, Michael W., Dickson, Dennis W. , Eckman, Christopher B., Dickson, Dennis W

The FASEB Journal | June 29, 2005 | Volume: 19 | Issue: 11 | Pages: 1549-1551

10.1096/fj.05-3826fje Get It

ABSTRACT Globoid cell leukodystrophy (GLD) or Krabbe disease is a devastating, degenerative neurological disorder caused by mutations in the galactosylceramidase (GALC) gene that severely affect enzyme activity. Currently, treatment options for this disorder are very limited. Enzyme replacement therapy (ERT) has been shown to be effective in lysosomal storage disorders with predominantly peripheral manifestations such as type I Gaucher's and Fabry's disease. Little however is known about the possible benefit of ERT in GLD, which has a substantial central nervous system component. In this study, we examined the effect of peripheral GALC injections in the twitcher mouse model of the disease. Although we were unable to block the precipitous decline that normally occurs just before death, we did observe significant early improvements in motor performance, a substantial attenuation in the initial failure to thrive, and an increase in life span. Immunohistochemical and activity analyses demonstrated GALC uptake in multiple tissues, including the brain. This was associated with a decrease in the abnormal accumulation of the GALC substrate psychosine, which is thought to play a pivotal role in disease pathology. These results indicate that peripheral ERT is likely to be beneficial in GLD.